Core Viewpoint - Shenzhen's Industrial and Information Technology Bureau has issued the "Shenzhen 'Artificial Intelligence +' Advanced Manufacturing Action Plan (2026-2027)", focusing on accelerating innovation and transformation in drug research and development, cell and gene therapy, and precision medical services [1] Group 1: Action Plan Objectives - The plan aims to promote technological innovation in key areas such as drug target discovery and validation, drug design, high-throughput drug screening, DNA-encoded compound library screening, computer-aided drug design, virtual screening, and gene locus screening related to drug therapy [1] - It supports the establishment of major platforms for AI-driven drug research and development, enhancing the integration of technological resources [1] Group 2: AI and Biotechnology Integration - The initiative emphasizes the deep integration of artificial intelligence and biotechnology (AI+BT) to accelerate advancements in the sector [1]

| 地区 | 2026产业布局 | | --- | --- | | 广东 | 未来产业:第六代移动通信、量子科技、细胞与基因治疗、脑科学与脑机接口、氢能 及先进核能、深海探测、具身智能新兴产业:种业和种畜禽、海洋油气、商业航天(卫 | | | 星研发制造、火箭总装测试、卫星数据应用)、低空经济、绿色核能、游戏出海、数 | | | 智加工、跨境电商直播 | | 江苏 | 未来产业:深海空天、生物医药、脑机接口、量子科技 | | 山东 | 新兴支柱产业:人工智能(机器人和智能装备)、生物医药、新能源汽车(机电电控、 | | | 智能网联)、航空航天(火箭、卫星制造、航天配套)与低空经济 | | 浙江 | 新兴支柱产业:新材料、新能源、集成电路、航空航天、低空经济、生物医药、视觉 健康 | | 四川 | 优势矿产资源深加工、新能源新材料、先进核电:算力、数据、人工智能、电子信息 "四大产业"、先进装备、航空航天及电子(低空飞行器制造、低空动力系统、航空机 载零部件等产业)、矿山机械、应急救援、文体康旅、山地农业等专用装备及配套产 | | | 业、生物制造、具身智能创新药研发、新型疫苗、血液制品、活体、干细胞等生物技 ...

多地布局未来产业 "十四五"以来，我国在未来产业前沿领域加快科技布局，在人工智能、生物制造、量子信息、氢能等一 批未来产业关键领域取得突破。"十五五"规划建议进一步明确，推动量子科技、生物制造、氢能和核聚 变能、脑机接口、具身智能、第六代移动通信等成为新的经济增长点。 国研新经济研究院创始院长朱克力对《中国经营报》记者表示，未来产业具有前瞻性、战略性、颠覆性 等特点，关乎科技产业制高点与发展主动权的争夺。中共中央政治局第二十四次集体学习传递出"稳中 求进、梯度培育"的明确导向，既强调立足客观条件、发挥比较优势，又要求统筹当前与长远，避免盲 目跟风与重复建设。 党的二十届四中全会明确提出，培育壮大新兴产业和未来产业。随着国家层面的定向部署，地方发展步 伐紧随其后。目前，全国31个省（区、市）两会均已召开，浙江、北京、广东等地都将未来产业发展规 划纳入2026年《政府工作报告》。 受访业界专家认为，这是立足强国建设与民族复兴战略高度的前瞻布局，更是把握新一轮科技革命和产 业变革机遇的关键之举。此举彰显未来产业已成为培育新质生产力、构建现代化产业体系的核心抓手， 为"十五五"时期产业发展锚定主攻方向与推进路径。 中 ...

Core Viewpoint - The Chinese pharmaceutical and medical device industry is entering a new phase of "systematic going global," supported by national platforms and multi-dimensional efforts from enterprises [1] Policy Support - The "systematic going global" initiative is receiving unprecedented systematic support, with the issuance of the first "overseas drug price certificate" in January 2026, bolstering the global pricing of China's pharmaceutical industry [2] - A multi-layered market connection network is being formed, with the National Healthcare Security Administration promoting differentiated development in regions like Guangxi, Xinjiang, Tianjin, and Ningbo, targeting Southeast Asia, Central Asia, and Central and Eastern Europe [2] - Multiple government departments, including the Ministry of Commerce and the National Medical Products Administration, are collaborating to reduce institutional costs and information barriers for enterprises going global [2] Industry Transformation - The export structure of China's pharmaceutical and medical device industry is shifting from low-value consumables to high-value innovative products, with a significant increase in the licensing-out transactions of innovative drugs expected to exceed $130 billion by 2025 [3] - Leading companies like United Imaging Healthcare and Mindray Medical are seeing a continuous increase in overseas revenue, successfully entering high-end hospital markets in Europe and the U.S. [3] Strategic Recommendations - Companies need to solidify their innovation foundation by focusing on unmet clinical needs and building proprietary technology platforms in advanced fields like ADCs, bispecific antibodies, and gene therapy [3] - Utilizing capital tools for overseas strategic layout is essential, such as raising funds through targeted placements for overseas clinical research and acquisitions of quality overseas targets [4] - Implementing differentiated market strategies is crucial, with companies needing to adopt localized thinking in different markets, maximizing product value through partnerships in mature markets and engaging in local production in emerging markets [4]

Core Insights - The Chinese medical device and pharmaceutical industry is entering a new phase of "systematic going global," supported by national platforms and multi-dimensional corporate efforts [1] Policy Support - The "systematic going global" initiative is receiving unprecedented systematic support, with the issuance of the first "overseas drug price certification" in January 2026, facilitating the global pricing of Chinese pharmaceuticals [2] - A multi-layered market connection network is being established, with the National Healthcare Security Administration promoting differentiated development in regions like Guangxi, Xinjiang, Tianjin, and Ningbo to expand services to countries along the Belt and Road [2] - Multiple government departments, including the Ministry of Commerce and the National Medical Products Administration, are collaborating to reduce institutional costs and information barriers for companies going global [2] Industry Transformation - The export structure of China's medical device and pharmaceutical industry is shifting from low-value consumables to innovative products, with a significant increase in the value chain [3] - By 2025, the total value of China's innovative drug licensing transactions is expected to exceed $130 billion, with many innovative drug companies attracting interest from international giants [3] - Leading companies like United Imaging Healthcare and Mindray Medical are increasing their overseas revenue share, successfully entering high-end hospital markets in Europe and the U.S. [3] Strategic Recommendations - Companies need to solidify their innovation foundations by focusing on unmet clinical needs and building proprietary technology platforms in advanced fields like ADCs, bispecific antibodies, and gene therapy [4] - Utilizing capital tools for overseas strategic layout is essential, such as raising funds through targeted placements for overseas clinical research and acquisitions of quality overseas targets [4] - Implementing differentiated market strategies is crucial, with companies needing to adopt localized thinking in different markets, maximizing product value through partnerships in mature markets, and engaging in local production and health ecosystem development in emerging markets [4]

Group 1 - The core viewpoint of the articles emphasizes the deep integration of artificial intelligence (AI) with the real economy in China, particularly in Guangdong, which is driving explosive growth in high-end manufacturing, emerging consumption, and new business models [1][2]. - Guangdong aims to accelerate the development of the AI industry by 2026, establishing a global AI industry cooperation center in the Guangdong-Hong Kong-Macao Greater Bay Area and creating three core industrial clusters in Guangzhou, Shenzhen, and Dongguan [1][2]. - The province has launched various initiatives, including the "AI + Manufacturing" special action, and has developed numerous AI application scenarios and models, with 122 large models registered with national authorities [1][2]. Group 2 - As of now, China has over 6,200 AI companies, and AI large models are being integrated into various industries, expanding their application scenarios [2]. - Guangdong plans to implement action plans for AI empowerment in specific sectors such as home appliances, automotive, electronics, petrochemicals, and building materials, aiming to enhance traditional industries through leading enterprises [2]. - In the robotics sector, Guangdong will focus on enhancing the production capacity of embodied intelligent robots and aims to launch several flagship products by addressing the entire industry chain from technology to commercialization [2]. Group 3 - In the biomedicine sector, Guangdong is accelerating the layout of new industries such as medical formulations, cell and gene therapy, and brain-computer interfaces, along with a list of key scientific achievements for rapid commercialization [3]. - For the intelligent connected vehicle industry, Guangdong supports pilot city projects in Guangzhou and Shenzhen for integrated applications, promoting the approval and road testing of L3 autonomous driving vehicles [3].

Core Insights - The medical ETF (159828) has risen over 1%, indicating that the pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global expansion [1] - The industry is expected to experience a convergence of industrial, policy, and capital cycles by 2026, transitioning from "innovation narrative" to "value realization," which may lead to performance inflection points and valuation restructuring [1] Industry Trends - The next generation of innovative therapies, including ADCs, bispecific/multispecific antibodies, cell and gene therapies, and small nucleic acids, are highlighted as key areas of focus [1] - The impact of centralized procurement on medical devices is diminishing, with over half of the policy coverage achieved; the coverage rates for high-value consumables, low-value consumables, in vitro diagnostics, and medical equipment are 58%, 35%, 23%, and 3% respectively [1] - Domestic medical device companies are making breakthroughs in high-end fields such as photon-counting CT and aortic regurgitation valves, with rapid growth in exports expected (medical device exports are projected to grow by 7.3% year-on-year from January to November 2025) [1] Investment Recommendations - Companies that can quickly achieve volume growth through price adjustments post-centralized procurement, as well as those benefiting from equipment upgrades driving procurement growth, are recommended for attention [1] - The medical ETF tracks the CSI Medical Index (399989), which selects listed companies in medical devices, medical services, and medical information technology, reflecting the overall performance of the medical theme [2] - The index is characterized by high growth attributes and industry concentration, influenced by aging trends, consumption upgrades, and policy guidance [2]

Core Viewpoint - The pharmaceutical and medical device sectors in China are expected to experience a convergence of industrial, policy, and capital cycles by 2026, presenting significant investment opportunities in innovative therapies and medical devices [1] Pharmaceutical Industry - The Chinese innovative drug sector is anticipated to reach a performance inflection point and valuation restructuring, with a focus on next-generation therapies such as ADCs, bispecific/multispecific antibodies, cell and gene therapies, and small nucleic acids [1] - Research and development spending by pharmaceutical companies is showing marginal improvement, with opportunities for domestic substitution and breakthroughs in mid-to-high-end products [1] Medical Device Industry - The impact of centralized procurement policies is gradually diminishing, while overseas markets continue to grow rapidly, suggesting a recovery in the performance of related companies [1] - Investment focus should be on rapidly scaling products post-procurement implementation and medical device companies driven by equipment upgrades [1] Blood Products Market - The demand for blood products and the volume of plasma collection are consistently increasing, with resources concentrating among leading companies in the sector [1] Investment Opportunities - The overall pharmaceutical industry is entering a critical phase of innovation realization and global expansion, with investment opportunities concentrated in innovative companies that possess global competitiveness [1] ETF Overview - The Guotai Innovation Pharmaceutical ETF (159377) tracks the Innovation Pharmaceutical Index (399275), which has a daily price fluctuation limit of 20%, focusing on companies with high R&D investment and innovation capabilities in the pharmaceutical sector [1]

Core Viewpoint - The pharmaceutical and biotechnology sector has shown resilience and growth potential in 2023, driven by policy support and industry transformation, with a clear focus on innovation and cost control shaping the industry landscape [1][5]. Industry Performance - The pharmaceutical and biotechnology sector has achieved a weighted average increase of 30.64% in market capitalization as of December 8, 2023, ranking 14th among 31 primary industries, but underperforming the CSI 300 index by 3.82 percentage points [1]. - The sector has exhibited significant internal differentiation, with innovation-driven segments outperforming others, such as biopharmaceuticals and medical R&D outsourcing, which saw increases of 57.07%, 54.68%, and 51.87% respectively, while traditional segments like traditional Chinese medicine and vaccines lagged behind [2]. Key Factors for Growth - The strong performance of the innovative drug industry chain is attributed to four core factors: exceeding expectations in earnings from leading companies like BeiGene and WuXi AppTec, continuous implementation of supportive policies, increased activity in domestic innovative drug business development (BD) transactions, and substantial clinical data disclosures at global academic conferences [2][3]. Financial Metrics - For the first three quarters of 2023, the pharmaceutical and biotechnology sector reported total revenue of 18,461.96 billion yuan, a year-on-year decrease of 1.27%, while net profit attributable to shareholders was 1,410.97 billion yuan, down 1.63%. However, the third quarter showed signs of recovery with a revenue increase of 1.21% and a net profit increase of 3.79% [4]. Policy Support - The "14th Five-Year Plan" emphasizes support for innovative drugs and medical devices, transitioning from process optimization to comprehensive empowerment across the industry chain, with a focus on key technological breakthroughs in areas such as dual antibodies, ADCs, and digital medicine [5]. Investment Opportunities - Three main investment themes are highlighted: 1. The innovative drug sector, which is expected to be the strongest investment theme due to policy support and market expansion [6]. 2. The CXO sector, benefiting from improved demand for innovative drug development and showing significant performance improvements [6]. 3. Consumer healthcare companies, which are anticipated to see a recovery in demand and performance due to supportive policies [6]. Technological Integration - The integration of AI technology into the biopharmaceutical industry is expected to enhance research efficiency and product development, with AI applications improving diagnostic processes and overall healthcare delivery [7].

Core Insights - The 25th China Private Equity Annual Conference will be held in Shenzhen from February 2-5, 2025, focusing on innovation in pharmaceuticals and life sciences [2] - The "Innovation Drugs and Life Science Summit" will discuss key advancements in biotechnology, including AI-driven drug development, cell and gene therapy, and medical device innovation [3] Group 1: Event Details - The conference is organized by Qingke Holdings, Investment界, and co-hosted by Huaitong Financial Holdings and Nanshan Zhanxin Investment [2] - A special summit on innovative drugs and life sciences will take place on December 4, featuring discussions on industry trends and investment opportunities [2][3] Group 2: Discussion Topics - Key topics include AI-driven models for next-generation drug development, the new era of innovative medical devices, and collaboration between CXOs and VCs to create a new ecosystem for innovative drugs [5] - Roundtable discussions will feature prominent figures from various sectors, including academia, industry, and investment, providing deep insights into the future of medical investments [7]